Mackenzie Financial Corp Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Mackenzie Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 07, 2022	SELL	$144.95 - $152.29 $27,975 - $29,391	-193 Reduced 4.54%	4,060 $614,000
Q2 2022 Aug 10, 2022	SELL	$83.14 - $145.99 $1.57 Million - $2.75 Million	-18,855 Reduced 81.6%	4,253 $620,000
Q1 2022 May 13, 2022	BUY	$110.08 - $142.92 $2.19 Million - $2.85 Million	19,920 Added 624.84%	23,108 $2.74 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $2,592 - $3,860	26 Added 0.82%	3,188 $439,000
Q3 2021 Nov 08, 2021	BUY	$98.85 - $138.91 $312,563 - $439,233	3,162 New	3,162 $439,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.